Eloxx Pharmaceuticals Q3 net loss widens on higher costs

By Reuters News


Overview

  • US rare kidney disease drug developer's Q3 net loss widened from prior year

  • Higher R&D and G&A costs drove increased quarterly loss


Outlook

  • Eloxx expects cash and cash equivalents to fund operations into 2028


Result Drivers

  • CLINICAL TRIAL SPENDING - Higher R&D expenses due to initiation of Phase 2b EXACT study and increased personnel costs

  • ADMINISTRATIVE COSTS - G&A expenses rose on higher professional fees, personnel, and facility costs

  • INTEREST INCOME - Higher interest income on increased cash balances following June 2026 public offering


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Loss

$5.54 mln

Q3 Income from Operations

-$5.95 mln

Q3 Loss Per Basic Share

$0.49

Q3 Operating Expenses

$5.95 mln


Reuters Recommended Reads

  • Nov 13 - PDS Biotechnology Q3 net loss narrows on lower R&D costs

  • Nov 13 - Inhibrx Q3 net loss widens on higher G&A expenses

  • Nov 13 - Aardvark Therapeutics Q3 net loss widens, misses estimates


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.